IDO1 antibody

Catalog No. ABIN1169196

Cited in 5+ publications. The Rabbit Polyclonal anti-IDO1 antibody (ABIN1169196) specifically detects IDO1 in WB, ELISA, ICC and FACS. The antibody is reactive with Human samples.

Quick Overview for IDO1 antibody (ABIN1169196)

Target: IDO1 (Indoleamine 2,3-Dioxygenase 1 (IDO1))

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This IDO1 antibody is un-conjugated

Application: Western Blotting (WB), ELISA, Immunocytochemistry (ICC), Flow Cytometry (FACS)

Product Details anti-IDO1 Antibody

Purpose: anti-IDO (human), pAb

Specificity: Recognizes human IDO1. Detects a band of ~45 kDa by Western blot.

Characteristics: Polyclonal Antibody. Recognizes human IDO. Detects a band of ~45 kDa by Western blot. Source: Rabbit. Applications: ELISA, FACS, ICC, WB. Liquid. 0.2μm-filtered solution in PBS, pH 7.4. Contains no preservatives. IDO catalyzes the first and rate-limiting step in the main pathway of human tryptophan catabolism, the kynurenine pathway. Proinflammatory mediators, such as endotoxin and IFN-gamma induce the expression of IDO in several tissues. IDO-dependent suppression of T-cell responses might function as natural immunoregulatory mechanism. Physiological IDO activity has been implicated in T-cell tolerance to tumors, dysfunctional selftolerance in non-obese diabetic (NOD) mice, and as a protective negative regulator in autoimmune disorders.

Sterility: 0.2 μm filtered

Immunogen: Recombinant human IDO1.

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: 0.2μm-filtered solution in PBS, pH 7.4.

Preservative: Without preservative

Handling Advice: After opening, prepare aliquots and store at -20 °C.Avoid freeze/thaw cycles.

Storage: 4 °C,-20 °C

Storage Comment:

+4°C

-20°C

Stable for at least 6 months after receipt when stored at -20°C.

Expiry Date: 6 months

References for anti-IDO1 antibody (ABIN1169196)

Pietra, Manzini, Rivara, Vitale, Cantoni, Petretto, Balsamo, Conte, Benelli, Minghelli, Solari, Gualco, Queirolo, Moretta, Mingari: "Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity." in: Cancer research, Vol. 72, Issue 6, pp. 1407-15, (2012) (PubMed).

Opitz, Litzenburger, Opitz, Sahm, Ochs, Lutz, Wick, Platten: "The indoleamine-2,3-dioxygenase (IDO) inhibitor 1-methyl-D-tryptophan upregulates IDO1 in human cancer cells." in: PLoS ONE, Vol. 6, Issue 5, pp. e19823, (2011) (PubMed).

Curti, Trabanelli, Onofri, Aluigi, Salvestrini, Ocadlikova, Evangelisti, Rutella, De Cristofaro, Ottaviani, Baccarani, Lemoli: "Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells." in: Haematologica, Vol. 95, Issue 12, pp. 2022-30, (2010) (PubMed).

Maby-El Hajjami, Amé-Thomas, Pangault, Tribut, DeVos, Jean, Bescher, Monvoisin, Dulong, Lamy, Fest, Tarte: "Functional alteration of the lymphoma stromal cell niche by the cytokine context: role of indoleamine-2,3 dioxygenase." in: Cancer research, Vol. 69, Issue 7, pp. 3228-37, (2009) (PubMed).

Boasso, Herbeuval, Hardy, Anderson, Dolan, Fuchs, Shearer: "HIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells." in: Blood, Vol. 109, Issue 8, pp. 3351-9, (2007) (PubMed).

Target Details for IDO1

Target: IDO1 (Indoleamine 2,3-Dioxygenase 1 (IDO1))

Alternative Name: IDO

Background:

Alternate Names/Synonyms: Indoleamine 2,3-dioxygenase 1, IDO, INDO

Product Description: IDO1 is a heme enzyme that catalyzes the first and rate-limiting step in the main pathway of human tryptophan catabolism, the kynurenine pathway, causing depletion of tryptophan which can lead to halted growth of microbes as well as T cells. IDO1 is an immune checkpoint protein, thought to play a role in a variety of pathophysiological processes such as antimicrobial and antitumor defense, neuropathology, immunoregulation and antioxidant activity. Cancer cells are able to evade the immune system is by hijacking the checkpoint proteins. Increased IDO1 protein levels drive growth arrest and apoptosis of the effector T cells, a group of immune cells that mediate the immune system's ability to destroy pathogens. By reducing the number of effector T cells, IDO1 overexpression prevents the immune system from effectively destroying cancer cells. IDO1 overexpression has been observed in a wide range of human cancers such as prostatic, colorectal, pancreatic, cervical, gastric, ovarian, head or lung cancer. Physiological IDO1 activity has been implicated in T cell tolerance to tumors, dysfunctional selftolerance in non-obese diabetic (NOD) mice, and as a protective negative regulator in autoimmune disorders.

UniProt: P14902

Pathways: Activated T Cell Proliferation